FBR Capital Markets initiated coverage on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note released on Wednesday morning, TheFlyOnTheWall.com reports. The firm issued a market perform rating and a $2.00 target price on the stock.
FBR Capital Markets has also updated their ratings on a number of other healthcare stocks in the last week. The firm initiated coverage on shares of Valeant Pharmaceuticals. They issued an outperform rating on that stock and set a $130.00 price target. Also, FBR Capital Markets raised its price target on shares of Teck Resources Limited from $30.00 to $35.00. They have an outperform rating on that stock.
Amarin Co. plc (NASDAQ:AMRN) opened at 1.641 on Wednesday. Amarin Co. plc has a 1-year low of $1.59 and a 1-year high of $14.30. The stock’s 50-day moving average is $4.95 and its 200-day moving average is $5.9. The company’s market cap is $283.3 million.
Amarin Co. plc (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. On average, analysts predict that Amarin Co. plc will post $-1.34 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on AMRN. Analysts at Citigroup Inc. downgraded shares of Amarin Co. plc to a neutral rating in a research note to investors on Friday, October 18th. Finally, analysts at Roth Capital cut their price target on shares of Amarin Co. plc from $15.00 to $5.00 in a research note to investors on Thursday, October 17th. They now have a buy rating on the stock. Eleven analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Amarin Co. plc currently has a consensus rating of Hold and an average price target of $6.21.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.